These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 24770721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL, Evans T, Pearmain P, Askew S, Singh K, Chan KK, Ganesan R, Hirschowitz L.
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [Abstract] [Full Text] [Related]

  • 3. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Cuesta-Guardiola T, Peregrin I, Mendizabal E, Lizarraga S, Ortiz-Quintana L.
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G, Oben J, Prenen L, Schobbens JC, Vlasselaer J, Van Holsbeke C, Debrock G, Van Eycken P, de Jonge E.
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Perioperative morbidity and mortality in octogenarians with ovarian cancer.
    Walters CL, Schneider KE, Whitworth JM, Fauci JM, Smith HJ, Barnes MN, Straughn JM.
    Int J Gynecol Cancer; 2013 Jul; 23(6):1006-9. PubMed ID: 23714708
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J.
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [Abstract] [Full Text] [Related]

  • 15. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D, Wu LY, Wang XB, Li XG.
    Asian Pac J Cancer Prev; 2015 Jun; 16(6):2369-73. PubMed ID: 25824766
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 Jun; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.